Morgan Stanley Virax Biolabs Group LTD Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
About Virax Biolabs Group Ltd
- Ticker VRAX
- Exchange
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,374,100
- Market Cap $20.4M
- Description
- Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid te...